Review
Published on 22 Feb 2023
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1130617
- 2,361 views
- 2 citations
Type at least 3 characters
1,548 articles
Articles
Review
Published on 22 Feb 2023
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1047554
- 1,396 views
Original Research
Published on 21 Feb 2023
Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1083088
- 1,089 views
- 1 citation
Editorial
Published on 21 Feb 2023
Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1157555
- 1,166 views
- 2 citations
Editorial
Published on 20 Feb 2023
Editorial: Biology and treatment of high-risk CLL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1109950
- 1,133 views
Original Research
Published on 17 Feb 2023
Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1108837
- 2,145 views
Case Report
Published on 17 Feb 2023
Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1116418
- 1,841 views
Systematic Review
Published on 16 Feb 2023
Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1071268
- 2,141 views
Original Research
Published on 16 Feb 2023
Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120867
- 1,198 views
- 1 citation
Original Research
Published on 16 Feb 2023
Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: A single-center study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1116205
- 1,387 views
- 2 citations
Original Research
Published on 15 Feb 2023
A diagnostic scoring model of ENKTCL in the nose-Waldeyer’s ring based on logistic regression: Differential diagnosis from DLBCL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1065440
- 1,024 views
Original Research
Published on 15 Feb 2023
Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1130899
- 1,390 views
- 1 citation
Correction
Published on 14 Feb 2023
Corrigendum: Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1132485
- 571 views
Editorial
Published on 14 Feb 2023
Editorial: Epidemiological trends in hematological malignancies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1151774
- 1,054 views
Review
Published on 14 Feb 2023
Measurable residual disease in chronic lymphocytic leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1112616
- 3,779 views
- 1 citation
Original Research
Published on 14 Feb 2023
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1117815
- 2,082 views
- 5 citations